Facial hyperhidrosis: Best practice recommendations and special considerations

Cutis

Volumn 79, Issue 5 SUPPL., 2007, Pages 29-32

  Glaser, Dee Anna ^a   Hebert, Adelaide A ^b,e   Pariser, David M ^c   Solish, Nowell ^d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ALGORITHM; ARTICLE; FACE; HUMAN; HYPERHIDROSIS; INTRADERMAL DRUG ADMINISTRATION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REIMBURSEMENT;

ALGORITHMS; BOTULINUM TOXIN TYPE A; FACE; HUMANS; HYPERHIDROSIS; INJECTIONS, INTRADERMAL; INSURANCE, HEALTH, REIMBURSEMENT; NEUROMUSCULAR AGENTS; QUALITY OF LIFE;

EID: 34250619716     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Glaser DA, Hebert AA, Pariser DM, et al. Palmar and plantar hyperhidnisis: best practice recommendations und special considerations. Cutis. 2007;79(suppl 5): 18-28.
2. Lear W, Kessler E, Solish N, et al. An epidemiological study of hyperhidrosis. Dermatol Surg. 2007;.33(1 spec no): S69-S75.
3. International Hyperhidrosis Society. Drugs/medications known to cause diaphoresis. Available at: http: //sweathelp.org/pdf/Diaphoretic_Drugs.pdf. Accessed December 14, 2006.
4. Atkins JL, Butler PE. Hyperhidrosis: a review of current management. Plast Reamstr Surg. 2002;110:222-228.
5. Hornberger J, Grimes K, Naumann M, et al, the MultiSpecialty Working Group on the Recognition, Diagnosis, and Treatment of Primary Focal Hyperhidrosis. Recognition, diagnosis, and treatment, of primary focal hyperhidrosis. ; Am Acad Dermatol. 2004;51:274-286.
6. Botox Cosmetic [package insert]. Irvinc, Calif: Allergan, Ine; 2005.
7. Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol. 2002;1.38:510-514.
8. Botox [package insert]. Irvine, Calif: Allergan, Inc; 2006.
9. Carruthers J, Fagien S, Matarasso SL, and the Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg. 2004;114(suppl 6):3S-22S.
10. Fujita M, Mann T, Mann O, et al. Surgical pearl: use of nerve blocks for botulinum toxin treatment of palmarplantar hyperhidrosis. J Am Acad Dermatol. 2001;45:587-589.
11. Kinkelin I, Hund M, Naumann M, et al. Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol. 2000;143:824-827.
12. Sanli H, Ekmekci P, Cenk Akbostanci M. Idiopathic localized crossed (left side of the upper part of the body, right side of the lower part of the body) hyperhidrosis: successful treatment of facial area with botulinum A toxin injection. Dermatol Surg. 2004;.30:552-554.
13. Tan SR, Solish N. Long-term efficacy and quality of life in the treatment of focal hyperhidrosis with botulinum toxin A. Dermatol Surg. 2002;28:495-499.
14. Hart AC, Hopkins CA, Ford B, eds. International Classification of Diseases, 9th Revision: Clinical Modification. 6th ed. Salt Lake City, Utah: Ingenix, Inc; 2005.
15. American Medical Association. CPT 2005; Current Procedural Terminology, Chicago, 111: American Medical Association; 2004-
16. American Medical Association. CPT 2006: Current Procedural Terminology. Chicago, 111: American Medical Association; 2005.